資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

Global Allergic Rhinitis Market Research Report—Forecast till 2025

  • LinkedIn
  • facebook
  • Twitter
出版日期:2020/12/01
頁  數:129頁
文件格式:PDF
價  格:
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
線上訂購或諮詢
Global Allergic Rhinitis Market: Information by Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), Treatment (Antihistamines, Corticosteroids, Immunotherapy, Decongestants and others), Route of Administration (Oral, Nasal and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Stores) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis
Allergic Rhinitis Market is expected to register a CAGR of 3.10% to reach USD 15064.12 Million by the year 2025. The Global Allergic Rhinitis Market is projected to expose profitable growth during the forecast period. Some of the significant factors characterizing the market growth are the increasing incidence of allergic rhinitis and increasing government initiatives to spread awareness about allergic diseases. However, the side-effects related usage of Allergic Rhinitis is anticipated to limit market growth over the forecast period. Allergic rhinitis, also known as hay fever, is an allergic disease associated with the nose. The allergic rhinitis affects when the immune system of the human body becomes clarified and overreacts to specific allergens in the environment, which are generally not harmful to most of the people. Allergic rhinitis may be classified as three different types viz., seasonal, perennial, and occupational. The increasing prevalence of allergic rhinitis, increasing government initiatives to promote awareness regarding allergic rhinitis, and growing healthcare expenditure and expansion of the private healthcare system is likely to drive the growth of the global allergic rhinitis market during the forecast period. For instance, according to the European Academy of Allergy and Clinical Immunology (EAACI), stated that over 150 million Europeans suffer from chronic allergic disease, out of which 100 million Europeans suffer from allergic rhinitis.

Market Segmentation
By type the Global Allergic Rhinitis Market has been segmented into Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis and Occupational Allergic Rhinitis. The antihistamines segment held a share of 40.4% in 2018. By Treatment the Global Allergic Rhinitis Market has been divided into Antihistamines, orticosteroids, Decongestants, Immunotherapy, Intranasal Anticholinergicsa and Others. By Route of Administration the global allergic rhinitis market has been segmented into Nasal, Oral and Others. Based on distribution channel the Global Allergic Rhinitis Market has been segmented into Retail Pharmacies, Hospital Pharmacies and Online Stores. Global Allergic Rhinitis Market into different regions like Americas broken into North America & Latin America. North America is sub-divided into US & Canada. Europe is split into the Western Europe and Eastern Europe. Western Europe is sub-divided into Germany, UK, France, Italy, Spain and Rest of Western Europe. Asia-Pacific including Japan, China, India, Australia, South Korea and Rest of Asia-Pacific, Middle East & Africa.

Regional Analysis
Geographically, the global allergic rhinitis market has been segmented into regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominates the global allergic rhinitis market owing to the presence of major market players in the region, strategic acquisitions by major players to augment product portfolio, growing cases of respiratory disorders, and availability of advanced medications for the treatment of allergic rhinitis. For the instance, the National Centre for Biotechnology Information (NCBI) stated that the prevalence of allergic rhinitis in the US is approximately 15%, which are physician-diagnosed. The European region holds the second-largest market share owing to the adoption of advanced processing by hospitals and patients in the European countries, and ongoing efforts made by Global Allergy and Asthma European Network to strengthen European research, spread excellence. Asia-Pacific are estimated to be the fastest-growing region in the global market due to the continuous developments in developing countries like India and China. Emerging economies are expected to explain maximum cases of allergic rhinitis due to tobacco smoke, exposure to air pollutants in the home and workplace, vehicular pollution, and indoor air pollution, this is likely to drive the growth of the market. This region is expected to grow at a CAGR of 3.65% during the forecast period of 2019 to 2025. The allergic rhinitis market in the Middle East & Africa is expected to witness a modest market growth rate from the year 2019 to 2025. The established countries in the Middle East, such as the UAE and Saudi Arabia are the ones with the maximum share in the allergic rhinitis market. The advanced healthcare infrastructure boosted healthcare expenditure and growing per capita disposable incomes of the people in these countries are some factors contributing to their large share of the market in this region.

Major Players
AstraZeneca, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Bayer AG, Sanofi, Boehringer Ingelheim, Merck & Co., ALK-Abello A/S, Novartis AG, Meda Pharmaceuticals, and others are some of the prominent players in the Global Allergic Rhinitis Market. Some of the projected onlookers for the Global Allergic Rhinitis Market are Allergic rhinitis drugs manufacturing companies, Research & development organizations and Academic institutes.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 14

1.2 KEY CONTRIBUTING FACTORS 15

2 Market Introduction
2.1 DEFINITION 16

2.2 SCOPE OF THE STUDY 16

2.3 RESEARCH OBJECTIVE 16

2.4 MARKET STRUCTURE 17

2.5 ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY
3.1 DATA MINING 18

3.2 SECONDARY RESEARCH 19

3.3 PRIMARY RESEARCH 20

3.3.1 BREAKDOWN OF PRIMARY RESPONDENTS 21

3.4 FORECASTING TECHNIQUES 22

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23

3.5.1 BOTTOM-UP APPROACH 24

3.5.2 TOP-DOWN APPROACH 24

3.5.3 DATA TRIANGULATION 25

3.5.4 VALIDATION 25

4 MARKET DYNAMICS
4.1 INTRODUCTION 26

4.2 DRIVERS 27

4.2.1 RISING PREVALENCE OF ALLERGIC RHINITIS 27

4.2.2 GOVERNMENT INITIATIVES TO CREATE AWARENESS 27

4.2.3 INCREASING HEALTHCARE EXPENDITURE 27

4.3 RESTRAINTS 28

4.3.1 PATENT EXPIRY 28

4.3.2 SIDE EFFECTS OF TREATMENT FOR ALLERGIC RHINITIS 28

4.4 OPPORTUNITIES 28

4.4.1 INCREASING DEMAND IN DEVELOPING COUNTRIES 28

4.4.2 MORE ADVANCED PRODUCTS 28

5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 29

5.1.1 BARGAINING POWER OF SUPPLIERS 30

5.1.2 BARGAINING POWER OF BUYERS 30

5.1.3 THREAT OF NEW ENTRANTS 30

5.1.4 THREAT OF SUBSTITUTES 30

5.1.5 INTENSITY OF RIVALRY 30

5.2 VALUE CHAIN ANALYSIS 31

5.2.1 R&D 32

5.2.2 MANUFACTURING 32

5.2.3 DISTRIBUTION & SALES 32

5.2.4 POST-SALES MONITORING 32

6 GLOBAL ALLERGIC RHINITIS MARKET BY TYPE
6.1 OVERVIEW 33

6.2 SEASONAL ALLERGIC RHINITIS 34

6.3 PERENNIAL ALLERGIC RHINITIS 34

6.4 OCCUPATIONAL ALLERGIC RHINITIS 35

7 GLOBAL ALLERGIC RHINITIS MARKET, BY TREATMENT
7.1 INTRODUCTION 36

7.2 ANTIHISTAMINES 37

7.3 CORTICOSTEROIDS 37

7.4 DECONGESTANTS 38

7.5 IMMUNOTHERAPY 38

7.6 INTRANASAL ANTICHOLINERGICS 38

7.7 OTHERS 39

8 GLOBAL ALLERGIC RHINITIS MARKET BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW 40

8.2 NASAL 41

8.3 ORAL 41

8.4 OTHERS 42

9 GLOBAL ALLERGIC RHINITIS MARKET BY DISTRIBUTION CHANNEL
9.1 OVERVIEW 43

9.2 RETAIL PHARMACIES 44

9.3 HOSPITAL PHARMACIES 44

9.4 ONLINE STORES 45

10 GLOBAL ALLERGIC RHINITIS MARKET, BY REGION
10.1 INTRODUCTION 46

10.2 AMERICAS 48

10.2.1 NORTH AMERICA 50

10.2.2 LATIN AMERICA 54

10.3 EUROPE 64

10.4 ASIA-PACIFIC 78

10.5 MIDDLE EAST & AFRICA 90

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION 95

12 COMPANY PROFILES
12.1 ASTRAZENECA 97

12.1.1 COMPANY OVERVIEW 97

12.1.2 FINANCIAL OVERVIEW 97

12.1.3 PRODUCTS/SERVICES OFFERED 98

12.1.4 KEY DEVELOPMENTS 98

12.1.5 SWOT ANALYSIS 99

12.1.6 KEY STRATEGIES 99

12.2 BOEHRINGER INGELHEIM 100

12.2.1 COMPANY OVERVIEW 100

12.2.2 FINANCIAL OVERVIEW 100

12.2.3 PRODUCTS/SERVICES OFFERED 101

12.2.4 KEY DEVELOPMENTS 101

12.2.5 SWOT ANALYSIS 102

12.2.6 KEY STRATEGIES 102

12.3 MERCK & CO., INC. 103

12.3.1 COMPANY OVERVIEW 103

12.3.2 FINANCIAL OVERVIEW 103

12.3.3 PRODUCTS/SERVICES OFFERED 104

12.3.4 KEY DEVELOPMENTS 104

12.3.5 SWOT ANALYSIS 105

12.3.6 KEY STRATEGIES 105

12.4 GLAXOSMITHKLINE PLC 106

12.4.1 COMPANY OVERVIEW 106

12.4.2 FINANCIAL OVERVIEW 106

12.4.3 PRODUCTS/SERVICES OFFERED 107

12.4.4 KEY DEVELOPMENTS 107

12.4.5 SWOT ANALYSIS 108

12.4.6 KEY STRATEGIES 108

12.5 JOHNSON & JOHNSON SERVICES, INC. 109

12.5.1 COMPANY OVERVIEW 109

12.5.2 FINANCIAL OVERVIEW 109

12.5.3 PRODUCTS/SERVICES OFFERED 110

12.5.4 KEY DEVELOPMENTS 110

12.5.5 SWOT ANALYSIS 111

12.5.6 KEY STRATEGIES 111

12.6 BAYER AG 112

12.6.1 COMPANY OVERVIEWS 112

12.6.2 FINANCIAL OVERVIEW 112

12.6.3 PRODUCTS/SERVICES OFFERED 113

12.6.4 KEY DEVELOPMENTS 113

12.6.5 SWOT ANALYSIS 114

12.6.6 KEY STRATEGIES 114

12.7 ALK-ABELLO A/S 115

12.7.1 COMPANY OVERVIEW 115

12.7.2 FINANCIAL OVERVIEW 115

12.7.3 PRODUCTS/SERVICES OFFERED 116

12.7.4 KEY DEVELOPMENTS 116

12.7.5 SWOT ANALYSIS 117

12.7.6 KEY STRATEGIES 117

12.8 MEDA PHARMACEUTICALS 118

12.8.1 COMPANY OVERVIEW 118

12.8.2 FINANCIAL OVERVIEW 118

12.8.3 PRODUCTS/SERVICES OFFERED 119

12.8.4 KEY DEVELOPMENTS 119

12.8.5 SWOT ANALYSIS 120

12.8.6 KEY STRATEGIES 120

12.9 SANOFI 121

12.9.1 COMPANY OVERVIEW 121

12.9.2 FINANCIAL OVERVIEW 121

12.9.3 PRODUCTS/SERVICES OFFERED 122

12.9.4 KEY DEVELOPMENTS 122

12.9.5 SWOT ANALYSIS 123

12.9.6 KEY STRATEGIES 123

12.10 NOVARTIS AG 124

12.10.1 COMPANY OVERVIEW 124

12.10.2 FINANCIAL OVERVIEW 124

12.10.3 PRODUCTS/SERVICES OFFERED 125

12.10.4 KEY DEVELOPMENTS 125

12.10.5 SWOT ANALYSIS 126

12.10.6 KEY STRATEGIES 126

13 APPENDIX
13.1 REFERENCES 127

13.2 RELATED REPORTS 127


















































回上頁